SEARCH · Search PubMed

Results for “THROMBOEMBOLISM”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,513 records · Page 84Linked to original sources

PubMed1998

[Chronic thromboembolic pulmonary hypertension: hemodynamic effects of selective pulmonary artery DSA with nonionic contrast media].

PURPOSE: This study evaluates the effects of pulmonary bolus injection of nonionic contrast medium on pulmonary artery pressure and resistance in patients with chronic thromboembolic pulmonary hypertension. METHODS: In 39 patients (age 52 +/- 15) haemodynamic measurements were performed during bolus injection of nonionic contrast medium in a control group (I), in moderately severe (II) and severe pulmonary hypertension (III). RESULTS: Initial inspiratory arrest caused significant pressure increase in all groups prior to bolus injection (delta PAsyst: 7.1 +/- 6.7 [I], 6.8 +/- 3.9 [II] und 7.2 +/- 7.9 mmHg p < 0.05). However, contrast bolus injection (25.1 +/- 2.3 ml iopamidol, 13.0 ml/s) caused only minor additional pressure increase (delta PAsyst: 2.2 +/- 1.4 [I], 2.7 +/- 1.9 [II] und 4.9 +/- 5.4 mmHg [III] p < 0.05). After angiography pulmonary artery pressure and vascular resistance was increased only moderately, predominantly in group III. Systemic vascular resistance was slightly decreased. CONCLUSION: In patients with moderately severe and severe chronic thromboembolic pulmonary hypertension bolus injection of nonionic contrast medium causes no major haemodynamic effects.

Adult↗

PubMed1999

Treatment of venous thromboembolism in cancer patients.

The occurrence of venous thromboembolism complicates the management of the patient with malignant disease because of the need for anticoagulant therapy. Cancer patients have an ongoing thrombotic stimulus due to the underlying cancer and its associated treatments, but are also considered to be at increased risk for anticoagulant-related bleeding. In recent years, the results of clinical trials have demonstrated the safety and efficacy of weight-adjusted subcutaneous low molecular weight heparin, administered at home, for patients with acute deep vein thrombosis. This approach is particularly attractive to patients with cancer where quality of life is an important consideration. There are no trials that specifically address the question of the duration of oral anticoagulant therapy in cancer patients. However, data can be extrapolated from trials evaluating the duration of oral anticoagulant therapy in other high-risk patients. Hence, cancer patients should continue oral anticoagulant therapy for as long as the cancer remains active (usually at least 6 months). There still remain a number of unanswered questions about the clinical management of thromboembolism in the cancer patient.

Administration, Cutaneous↗

PubMed1997

Diagnosis of thromboembolic disease during infancy and childhood.

Thromboembolic disorders are frequent complications in pediatric patients and the incidence seems to rise. Adult guidelines for thromboembolism do not hold for children because there are many age-related features. Congenital prethrombotic disorders play a major role in the pediatric population and activated protein C (APC) resistance is also the most frequently encountered problem. Acquired risk factors in children are central venous line thrombosis with serious complications, cardiac diseases such as cardiomyopathies, prosthetic heart valves and aneurysms, renal vein thrombosis, and nephrotic syndrome. Renal vein thrombosis primarily affects newborns. Children with the antiphospholipid antibody syndrome also have thromboses although less frequent than adults, but systemic lupus erythematosus is associated with a high incidence. Acute lymphoblastic leukemia is frequently associated with thrombosis in children, especially when complicated by APC resistance. The greatest risk of thrombosis in children is during the neonatal period, and again congenital prethrombotic states and catheter placement play a major role. The clinical manifestations in children reflect the site of the thrombosis and extensive laboratory evaluations and advanced diagnostic procedures must be employed to diagnose the thrombotic events.

Adolescent↗

PubMed1985

[Thromboembolism complications in ventriculo-atrial drainage of cerebrospinal fluid in childhood].

This report wants to call attention to the possible risks of thromboembolic complications of ventriculo-atrial shunts (Spitz-Holter valve). Among 126 children with ventriculo-atrial shunt we found four patients with severe thromboembolic complications. Two children died. The diagnostic and therapeutic possibilities are mentioned. Prophylaxis (prevention of infection, anticoagulation therapy and frequent followup investigation) is discussed; especially echocardiography is very useful for the early discovery of thrombotic deposits on the atrial catheter.

Cerebrospinal Fluid Shunts↗

PubMed1989

[Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery].

The effect of low-molecular weight (LMW) heparin fragment (one injection of 1500 aPTT [activated partial thromboplastin time]-U/24 h)--group 1--was compared with unfractionated (UF) heparin (3 x 5000 IU/24 h)--group 2--in a randomized prospective double-blind trial of 404 patients (202 patients in each group), aged 50 years or older, undergoing abdominal surgery. The two groups were well matched for thromboembolic risk factors. The first subcutaneous injection was made two hours preoperatively; postoperative injections continued for at least seven days. The radiofibrinogen test served as the test criterion. If positive, phlebography and lung sequence scanning were performed. On complete prophylaxis the thrombosis rate was nearly identical in the two groups--10.8% vs 11.4%. No pulmonary emboli were detected in either group if correctly treated. There was no significant difference between the two groups with respect to peroperative blood loss, re-operation rate and wound haematoma rate. But there was a significantly higher number of injection haematomas in group 2. These results suggest that a single daily injection of 1500 aPTT-U LMW heparin provides effective prophylaxis against postoperative venous thromboembolism.

Abdomen↗

PubMed1987

[Congenital protein C deficiency and thromboembolic diseases].

Besides its cofactor protein S and antithrombin III, protein C is one of the most important inhibitors of plasma coagulation. In seven members of a family as well as in three further unrelated patients, a congenital protein C deficiency with thromboembolic diseases including a coumarin necrosis was observed in two cases. Deficiency of protein C predisposes to the occurrence of thromboembolism, but the severity of the underlying heterozygotic genetic defect can also vary within the family. Long-term oral anticoagulation with phenprocoumon is the therapy of choice. Genetic counselling should always be carried out.

Adult↗

PubMed1996

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.

BACKGROUND: Patients who have had major trauma are at very high risk for venous thromboembolism if they do not receive thromboprophylaxis. We compared low-dose heparin and a low-molecular-weight heparin with regard to efficacy and safety in a randomized clinical trial in patients with trauma. METHODS: Consecutive adult patients admitted to a trauma center who had Injury Severity Scores of at least 9 and no intracranial bleeding were randomly assigned to heparin (5000 units) or enoxaprin (30 mg), each given subcutaneously every 12 hours in a double-blind manner, beginning within 36 hours after the injury. The primary outcome was deep-vein thrombosis as assessed by contrast venography performed on or before day 14 after randomization. RESULTS: Among 344 randomized patients, 136 who received low-dose heparin and 129 who received enoxaparin had venograms adequate for analysis. Sixty patients given heparin (44 percent) and 40 patients given enoxaparin (31 percent) had deep-vein thrombosis (P=0.014). The rates of proximal-vein thrombosis were 15 percent and 6 percent, respectively (P=0.012). The reductions in risk with enoxaparin as compared with heparin were 30 percent (95 percent confidence interval, 4 to 50 percent) for all deep-vein thrombosis and 58 percent (95 percent confidence interval, 12 to 87 percent) for proximal-vein thrombosis. Only six patients (1.7 percent) had major bleeding (one in the heparin group and five in the enoxaparin group, P=0.12). CONCLUSIONS: Low-molecular-weight heparin was more effective than low-dose heparin in preventing venous thromboembolism after major trauma. Both interventions were safe.

Adult↗

PubMed2003

Factors associated with recurrent venous thromboembolism in patients with malignant disease.

PURPOSE: The role of prophylactic vena cava filters (VCF) in patients with cancer is debated. Although VCF are often placed in patients with cancer after recurrence of venous thromboembolic events (VTE), identification of this subset of patients has not been well-defined. This study was undertaken to assess factors associated with increased risk for recurrent VTE. METHODS: All patients with a history of thromboembolism or malignant disease and who required a VCF because of failure of or contraindication to anticoagulation therapy were abstracted from the Michigan Filter Registry. Univariate analysis of potential risk factors for recurrent VTE and logistic regression models were used to identify associations between these variables and recurrent VTE. RESULTS: Ninety-nine patients (49 men, 50 women) with a mean age of 58 years were included in the study. New metastases occurred in 55% of patients, and 12% of patients had a history of VTE before cancer diagnosis. Corticosteroid agents were used during therapy in 48% of patients. Acute VTE was present in 52% of patients at cancer diagnosis, and in 34% of patients VTE was associated with new metastases. Recurrent VTE occurred in 40% of patients, and significant risk factors included presence of new metastases (odds ratio [OR], 3.3; 95% confidence interval [CI], 1.16-9.09; P =.02) and history of VTE (OR, 10.6; CI, 1.98-57.2; P =.006). Whereas a single episode of neutropenia did not reach significance (OR, 1.1; CI, 0.97-1.35; P =.11), multiple neutropenic episodes were significantly associated with recurrent VTE (P =.04). Smoking, hormone replacement therapy, decreased mobility, post-surgical state, and obesity were not independently associated with increased risk. Mean survival in this series was 30 months, and was significantly worse in patients with VTE at cancer diagnosis and with inability to tolerate anticoagulant therapy in conjunction with VCF. CONCLUSION: Patients with malignant disease may be at increased risk for recurrent VTE after development of new metastases or multiple episodes of neutropenia, especially those patients with a history of VTE. VCF may be a reasonable alternative to long-term anticoagulation therapy in this subgroup of patients at high risk patients, provided their quality of life is reasonable.

Adolescent↗

PubMed1991

Thromboembolism prophylaxis. Choosing the proper method for surgical patients.

The primary care physician can play a major role in preoperative consultation in terms of assisting the surgical team to reduce the risk of thromboembolism. A preoperative risk assessment takes into account the type and duration of surgery as well as the existence of risk factors such as age and underlying medical conditions. With careful communication, the consulting physician and surgical team can together select a method of preventing thromboembolism that will prove both safe and effective.

Anticoagulants↗

PubMed2003

Mixed arterial and venous thromboembolism in a person with HIV infection.

People with human immunodeficiency virus (HIV) infection are more susceptible to thromboembolic events. Venous thromboembolism (VTE) occurs frequently in HIV infected persons but arterial thrombosis has only rarely been reported. We describe a case of a person with HIV infection who developed an arterial thrombosis and 3 months later an extensive VTE. Several non-HIV and HIV related thrombogenic factors were identified.

Angiography↗

PubMed2002

Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review.

OBJECTIVE: To assess the incidence of clinically evident pulmonary emboli and deep vein thromboses in patients undergoing transurethral resection of the prostate (TURP) with the routine use of graduated elastic compression stockings (TED) in all patients and the addition of low-dose heparin in selected high-risk patients. PATIENTS AND METHOD: A retrospective analysis of clinically evident thromboembolic complications within 4 weeks of operation in 883 patients operated in a single hospital during a 4-year period. RESULTS: Four patients (0.45%) developed pulmonary emboli (PE), of which two (0.23%) were fatal. There was one clinically evident deep vein thrombosis (DVT) in a high-risk patient (0.11%). None of the 14 high-risk patients receiving additional low-dose heparin required a blood transfusion. CONCLUSION: Clinical thromboembolic complications following TURP are rare. TURP patients have a low risk for DVT, but an intermediate risk for pulmonary emboli. Pulmonary emboli may occur without identifiable risk factors and despite TED stocking prophylaxis.

Aged↗

PubMed1993

Tissue plasminogen activator: comparison of dose and route of administration in a rabbit model of thromboembolic stroke.

The thrombolytic activity of tissue plasminogen activator was evaluated in a rabbit model of thromboembolic stroke using both various concentrations (3, 5, and 10 mg/kg; 20% bolus with the remaining 80% given over 30 min.) and routes of administration (intravenous versus regional intra-arterial). An autologous tin-tagged clot was embolized to the brain via the carotid artery. Tissue plasminogen activator was then given at the doses and routes noted (n = 3 in all groups). Thrombolytic activity was followed by serial x-rays of the tin-laden clot over a four-hour period. The brains were then removed and subjected to gross inspection. Only the intravenous dose of 5 mg/kg tissue plasminogen activator produced greater than 50% clot lysis in all animals. Doses of t-PA higher (10 mg/kg) or lower (3 mg/kg) than this were less effective in producing thrombolysis, demonstrating greater than 50% clot lysis in only one animal of each group. We conclude that in this model of thromboembolic stroke the intravenous administration of tissue plasminogen activator is more effective than intra-arterial, and that the optimal dose is in the range of 5 mg/kg.

Animals↗

PubMedDate not supplied

Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus.

With improved disease survival, arterial thromboembolism has become an important cause of morbidity in patients with systemic lupus erythematosus (SLE). A number of conventional and non-conventional risk factors are associated with accelerated atherosclerosis. Regular surveillance and control of traditional risk factors is mandatory, and so is the appropriate use of the statins, anti-malarial agents, anti-platelet agents, and anti-coagulation for primary and secondary prevention of arterial thromboembolism in SLE patients. Judicious use of corticosteroids, calcineurin inhibitors, hormonal replacement therapy, and the cyclooxygenase 2 inhibitors is equally important.

Atherosclerosis↗

PubMed2026

Risk factors of venous thromboembolism in ICU patients: a systematic review and meta-analysis.

OBJECTIVE: This study aimed to identify risk factors associated with the development of VTE in patients admitted to the intensive care unit (ICU). METHODS: A systematic literature search was conducted via PubMed, Embase, Web of Science, and Cochrane databases up to 25 April 2025, to identify studies examining the association between risk factors and the occurrence of venous thromboembolism (VTE) in ICU patients. Data were pooled using odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: A total of 2465 relevant studies were identified through the systematic search, of which 30 were included in the meta-analysis. The pooled data showed that the following were significant risk factors for venous thromboembolism (VTE) in ICU patients: central venous catheterization (OR = 2.67, 95% CI: 1.67-4.28; I2 = 28%), invasive mechanical ventilation (OR = 2.08, 95% CI: 1.46-2.96; I2 = 0%), advanced age (OR = 2.06, 95% CI: 1.28-3.31; I2 = 86%), length of ICU stay (OR = 4.24, 95% CI: 1.43-12.57; I2 = 98%), malignancy (OR = 2.30, 95% CI: 1.03-5.12; I2 = 67%), elevated D-dimer levels (OR = 2.46, 95% CI: 1.37-4.40; I2 = 34%), and a history of VTE (OR = 2.84, 95% CI: 1.45-5.55; I2 = 51%). According to the GRADE assessment, the quality of evidence was rated as moderate for invasive mechanical ventilation, low for central venous catheterization and D-dimer levels, and very low for the remaining factors. CONCLUSION: Invasive mechanical ventilation, central venous catheterization, and elevated D-dimer levels are associated with VTE risk, supported by relatively high-quality evidence. These findings may help identify ICU patients at higher risk of VTE, inform the development of risk assessment models for patient stratification, and ultimately contribute to improved prognosis through optimal screening and management strategies.

Humans↗

PubMed2003

Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism?

An audit of the effect of anticoagulant prophylaxis in acute exacerbations of severe autoimmune haemolysis was undertaken. All cases of this disorder presenting to one institution over a 16 year period were reviewed. There were 28 patients who had a total of thirty six exacerbations of haemolysis. Anticoagulant prophylaxis had been introduced from 1992 following three cases with fatal pulmonary emboli. Venous thromboembolism occurred in 5 of 15 exacerbations without prophylaxis but in only one of 21 in which prophylaxis was given. It is suggested that auto-immune haemolysis increases the risk of thromboembolism but further studies are required to quantify the risks and to define optimal prophylactic regimens.

Adult↗

PubMed2002

Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery.

OBJECTIVES: This is a prospective study in the use of low molecular weight heparin (LMWH) for venous thromboembolism prophylaxis in the previously unstudied subset of patients undergoing elective urologic cancer surgery. METHODS: Thirty-eight patients undergoing elective urologic surgery were studied. Thirty-six had urologic malignancies. Pre-operative risk factors for venous thromboembolic disease were recorded. All patients received LMWH (dalteparin, Fragmin; Pharmacia, Stockholm, Sweden) subcutaneously on a daily basis beginning 1-2 hr before surgery and lasting for 3-7 days. Postoperative physical examination was used to check for clinical evidence of deep venous thrombosis (DVT). Clinical parameters such as physical examination and radiological testing were used to assess for evidence of DVT. Other data included intraoperative blood loss, transfusion requirements, postoperative bleeding complications, postoperative hematocrit and coagulation profiles, and local complications related to the subcutaneous injection of the LMWH. RESULTS: All patients completed the prophylaxis protocol. None developed DVT. Mean intraoperative blood loss was 735 mL and 12 patients received an average of 1 unit of blood transfusion. No unusual hemorrhagic events were noted intra- or post-operatively. No reactions to the LMWH were noted. Average hematocrit of postoperative day 3 was 30.7 and platelet count and coagulation profiles remained normal postoperatively. CONCLUSIONS: Low molecular weight heparins appear promising for DVT prophylaxis in high-risk urology patients.

Adult↗

PubMed2003

Estrogen and thromboembolic disorders: should patients stop hormones prior to cosmetic surgery?

Oral contraceptives and replacement estrogenic hormones have been associated with a significant risk of thromboembolism. Cosmetic surgery consists of elective procedures in otherwise healthy individuals. The prospect of thromboembolism should be diminished in these patients by avoiding those factors that may give rise to the problem. Stopping oral contraceptives and replacement estrogens three weeks before surgery to two weeks after surgery is not difficult for most patients and should be part of the custom and practice of all cosmetic surgeons.

Contraceptives, Oral, Hormonal↗

PubMed1999

Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.

Activated protein C resistance caused by factor VLeiden mutation is the most common inherited predisposing cause of venous thromboembolism, including pulmonary embolism (PE). We studied whether the incidence of factor VLeiden is higher among patients with PE evident at autopsy than in the general population. Paraffin-embedded fixed tissue blocks from all autopsy patients with diagnosed pulmonary thromboembolic disease during a 4-year period were collected for DNA extraction. Extraction and molecular analysis of the DNA was performed with an improved technique with an internal control to determine the presence of factor VLeiden mutation. Analysis of 82 autopsy cases with PE yielded 5 patients who were heterozygotes. Seventy-seven of the 82 patients analyzed were normal, and no homozygotes for factor VLeiden mutation were identified. This yielded a positive rate of 6% overall and 7% among white patients, which is similar to the incidence of heterozygotes in the white population. This study indicates that routine determination of factor VLeiden mutation is not warranted for patients with PE diagnosed at autopsy.

Adolescent↗